Search

Your search keyword '"Manso, Félix"' showing total 9 results
Start Over Author "Manso, Félix"
9 results on '"Manso, Félix"'

1. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

Author

Montesinos, Pau, Rayón, Chelo, Vellenga, Edo, Brunet, Salut, González, José, González, Marcos, Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, González, José D., Rivas, Concha, Tormo, Mar, Rubio, Vicente, Bueno, Javier, Manso, Félix, Milone, Gustavo, de la Serna, Javier, Pérez, Inmaculada, Pérez-Encinas, Manuel, Krsnik, Isabel, Ribera, Josep M., Escoda, Lourdes, Lowenberg, Bob, and Sanz, Miguel A.

Published
2011
Full Text
View/download PDF

2. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Author

Sanz, Miguel A., Montesinos, Pau, Rayón, Chelo, Holowiecka, Alexandra, de la Serna, Javier, Milone, Gustavo, de Lisa, Elena, Brunet, Salut, Rubio, Vicente, Ribera, José M., Rivas, Concha, Krsnik, Isabel, Bergua, Juan, González, José, Díaz-Mediavilla, Joaquín, Rojas, Rafael, Manso, Félix, Ossenkoppele, Gert, González, José D., and Lowenberg, Bob

Published
2010
Full Text
View/download PDF

3. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

Author

European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Investigación Sanitaria La Fe (España), Sobas, Marta, Rodriguez‐Veiga, Rebeca, Vellenga, Edo, Paluszewska, Monika, Serna, Javier de, García-Álvarez, Flor, Gil, Cristina, Brunet, Salut, Bergua, Juan, González-Campos, José A., Ribera, Josep-Maria, Tormo, Mar, González, Marcos, Fernández, Isolda, Benavente, Celina, González‐Sanmiguel, José D., Esteve, Jordi, Pérez-Encinas, Manuel, Salamero, Olga, Manso, Félix, Lowenberg, Bob, Sanz, Miguel Ángel, Montesinos, Pau, European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Investigación Sanitaria La Fe (España), Sobas, Marta, Rodriguez‐Veiga, Rebeca, Vellenga, Edo, Paluszewska, Monika, Serna, Javier de, García-Álvarez, Flor, Gil, Cristina, Brunet, Salut, Bergua, Juan, González-Campos, José A., Ribera, Josep-Maria, Tormo, Mar, González, Marcos, Fernández, Isolda, Benavente, Celina, González‐Sanmiguel, José D., Esteve, Jordi, Pérez-Encinas, Manuel, Salamero, Olga, Manso, Félix, Lowenberg, Bob, Sanz, Miguel Ángel, and Montesinos, Pau

Abstract

[Objective] The obesity/overweight may have an influence on APL outcomes., [Methods] This is the biggest multicentre analysis on 1320 APL patients treated with AIDA‐induction and risk‐adapted consolidation between 1996 and 2012. Patients body mass index (BMI) was classified as underweight (<18.5 kg/m2), normal (18.5‐25 kg/m2), overweight (25‐29.9 kg/m2), and obese (≥30 kg/m2) according to the World Health Organization (WHO) criteria., [Results and conclusions] Relationship between male gender, older age, and other known laboratory abnormalities in overweight/obese patients was significant. The induction mortality rate was significantly higher in APL with BMI ≥25 vs BMI <25 (10% vs 6%; P = .04). APL patients with BMI ≥25 had a trend to lower OS (74% vs 80%; P = .06). However, in the multivariate analysis, BMI did not retain the independent predictive value (P = .46). There was no higher incidence of differentiation syndrome with BMI ≥25, but there was a trend in obese. There was no difference in relapse rate according to the BMI. In summary, overweight/obesity does not represent an independent risk factor for APL outcomes. The influence of obesity in APL patients treated with chemotherapy‐free regimens remains to be established.

Published
2020

4. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry

Author

European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Salamero, Olga, Martínez-Cuadrón, David, Sobas, Marta, Benavente, Celina, Vives, Susana, Serna, Javier de, Pérez-Encinas, Manuel, Escoda, Lourdes, Gil, Cristina, Brunet, Salut, Ramos, Fernando, Esteve, Jordi, Amigo, M. Luz, Krsnik, Isabel, Manso, Félix, Arias, Jesús, González-Campos, José A., Serrano-López, Josefina, Oleksiuk, Jalanta, Barrios, Manuel, García-Boyero, Raimundo, Novo, Andrés, Sanz, Miguel Ángel, Montesinos, Pau, European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Salamero, Olga, Martínez-Cuadrón, David, Sobas, Marta, Benavente, Celina, Vives, Susana, Serna, Javier de, Pérez-Encinas, Manuel, Escoda, Lourdes, Gil, Cristina, Brunet, Salut, Ramos, Fernando, Esteve, Jordi, Amigo, M. Luz, Krsnik, Isabel, Manso, Félix, Arias, Jesús, González-Campos, José A., Serrano-López, Josefina, Oleksiuk, Jalanta, Barrios, Manuel, García-Boyero, Raimundo, Novo, Andrés, Sanz, Miguel Ángel, and Montesinos, Pau

Abstract

Acute promyelocytic leukemia is infrequent among patients aged ≥75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2017, among 2501 APL cases registered 120 were ≥75 years old. Treatment approaches were: AIDA regimen, 79 patients; ATRA alone, 23; 16, supportive care (SC) and 2, other strategies. Patients treated with AIDA were younger, had better ECOG and lower leukocytes. Complete remission (CR) was achieved in 65% of AIDA-group vs. 45% in the ATRA-group, being infections followed by bleeding the most frequent causes of induction death. Patients in CR after AIDA showed 3-year DFS of 73%. Our real-life series of very old APL patients provides a reference basis for future treatment strategies aiming to improve clinical outcomes in this challenging population.

Published
2019

5. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Author

Salamero, Olga, Martínez-Cuadrón, David, Sobas, Marta, Benavente, Celina, Vives, Susana, De la Serna, Javier, Pérez-Encinas, Manuel, Escoda, Lourdes, Gil, Cristina, Brunet, Salut, Ramos, Fernando, Esteve, Jordi, Amigo, Mariluz, Krsnik, Isabel, Manso, Félix, Arias, Jesús, González-Campos, José, Serrano, Josefina, Oleksiuk, Jalanta, and Barrios, Manuel

Subjects
ACUTE promyelocytic leukemia, MEDICAL protocols, OLDER patients
Abstract

Acute promyelocytic leukemia is infrequent among patients aged ≥75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2017, among 2501 APL cases registered 120 were ≥75 years old. Treatment approaches were: AIDA regimen, 79 patients; ATRA alone, 23; 16, supportive care (SC) and 2, other strategies. Patients treated with AIDA were younger, had better ECOG and lower leukocytes. Complete remission (CR) was achieved in 65% of AIDA-group vs. 45% in the ATRA-group, being infections followed by bleeding the most frequent causes of induction death. Patients in CR after AIDA showed 3-year DFS of 73%. Our real-life series of very old APL patients provides a reference basis for future treatment strategies aiming to improve clinical outcomes in this challenging population. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

6. Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens

Author

Montesinos, Pau, primary, Martínez-Cuadrón, David, additional, Rivas, Concha, additional, Brunet, Salut, additional, González-San Miguel, José David, additional, Rubio, Vicente, additional, Pérez, Cristina, additional, Manso, Félix, additional, Sánchez-Godoy, Pedro, additional, Escoda, Lourdes, additional, Amutio, Elena, additional, Zijlmans, Mark, additional, Tormo, Mar, additional, González, Marcos, additional, Rayón, Chelo, additional, Sayas, María José, additional, Ribera, Josep-Maria, additional, Deben, Guillermo, additional, Hernández-Martín, José, additional, Esteve, Jordi, additional, Vellenga, Edo, additional, and Sanz, Miguel, additional

Published
2013
Full Text
View/download PDF

7. Risk-adapted treatment of acute promyelocytic leukemia based on all-transretinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Author

Sanz, Miguel A., Montesinos, Pau, Rayón, Chelo, Holowiecka, Alexandra, de la Serna, Javier, Milone, Gustavo, de Lisa, Elena, Brunet, Salut, Rubio, Vicente, Ribera, José M., Rivas, Concha, Krsnik, Isabel, Bergua, Juan, González, José, Díaz-Mediavilla, Joaquín, Rojas, Rafael, Manso, Félix, Ossenkoppele, Gert, González, José D., and Lowenberg, Bob

Abstract

A risk-adapted strategy based on all-transretinoic acid (ATRA) and anthracycline monochemotherapy (PETHEMA LPA99 trial) has demonstrated a high antileukemic efficacy in acute promyelocytic leukemia. We designed a new trial (LPA2005) with the objective of achieving stepwise improvements in outcome. Between July 2005 and April 2009, low- and intermediate-risk patients (leukocytes < 10 × 109/L) received a reduced dose of mitoxantrone for the second consolidation course, whereas high- risk patients younger than 60 years of age received cytarabine combined with ATRA and idarubicin in the first and third consolidation courses. Of 372 patients attaining complete remission after ATRA plus idarubicin (92.5%), 368 proceeded to consolidation therapy. For low- and intermediate-risk patients, duration of neutropenia and thrombocytopenia and hospital stay were significantly reduced without sacrificing antileukemic efficacy, compared with the previous LPA99 trial. For high-risk patients, the 3-year relapse rate was significantly lower in the LPA2005 trial (11%) than in the LPA99 (26%; P= .03). Overall disease-free survival was also better in the LPA2005 trial (P= .04). In conclusion, the lower dose of mitoxantrone resulted in a significant reduction of toxicity and hospital stay while maintaining the antileukemic activity, and the combination of ATRA, idarubicin, and cytarabine for high-risk acute promyelocytic leukemia significantly reduced the relapse rate in this setting. Registered at http://www.clinicaltrials.govas NCT00408278.

Published
2010
Full Text
View/download PDF

9. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Author

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, and Sanz MA

Subjects
Adolescent, Adult, Aged, Child, Female, Humans, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute mortality, Male, Middle Aged, Prognosis, Remission Induction, Survival Analysis, Treatment Outcome, Young Adult, Anthracyclines therapeutic use, Antineoplastic Agents therapeutic use, Leukemia, Promyelocytic, Acute drug therapy, Mutation, Tretinoin therapeutic use, fms-Like Tyrosine Kinase 3 genetics
Abstract

Background: Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established., Design and Methods: We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005., Results: FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tandem duplication and D835 mutations, respectively. Internal tandem duplication was correlated with higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever, hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34, human leukocyte antigen-DR, and CD11b surface antigens. The FLT3-D835 mutation was not significantly associated with any clinical or biological characteristic. Univariate analysis showed higher relapse and lower survival rates in patients with a FLT3-internal tandem duplication, while no impact was observed in relation to FLT3-D835. The prognostic value of the FLT3-internal tandem duplication was not retained in the multivariate analysis., Conclusions: FLT3-internal tandem duplication mutations are associated with several hematologic features in acute promyelocytic leukemia, in particular with high white blood cell counts, but we were unable to demonstrate an independent prognostic value in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results